Ranbaxy Launches Generic Lipitor In Four Regional Markets

BMI view : Lipitor (atorvastatin)'s patent expiration brings significant revenue-earning opportunities for Ranbaxy Laboratories in Europe, particularly as cash-strapped governments are keen to promote the use of off-patented drugs in the battle with soaring drug spending. With regards to Germany, BMI believes the approval of generic Lipitor in the country may benefit Ranbaxy's German subsidiary, Basics GmbH , enabling to win a more substantial proportion of health insurance tenders in value terms.

To read the full article, please choose one of the following options: